Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI

Recruiting now · Phase 4

Conditions studied: HIV, HIV Associate Weight Loss, HIV-1 Infection, Integrase Inhibitors, HIV; HIV PROTEASE INHIB, Weight Change, Weight Loss

In brief

Patients who developed metabolic syndrome after initiation of HIV treatment or with antiretroviral therapy (ART) for at least 36 months, treated with second generation integrase inhibitors (BIC/TAF/FTC, DTG/ABC/3Tc or DTG+TDF/FTC) who have gained at least 10% of their total body weight after starting ART, with a body mass index ≥25 kg/m2 and body fat greater than 20% will be eligible to participate in this clinical trial. If they decide to participate, they will sign an informed consent. After this, a mobile application will randomly decide whether the participant will continue with their ART regimen or switch to another ART (listed in the guidelines as one of the main lines of treatment) containing doravirine/lamivudine/disoproxil fumarate tenofovir. Medical visits will be at 1 month, 3 months, 6 months, 9 months, and 12 months after get in to this protocol, with laboratory studies that evaluate fats, blood sugar, liver function, kidney function, and test for HIV control; in addition, each visit will be given self-fillable scales to evaluate neuropsychiatric disorders such as depression, anxiety, insomnia, satisfaction with treatment or symptoms associated with it.The aim of the study is to observe whether there is weight loss with the change in HIV treatment.

Key facts

Study ID: NCT06602622
Run by: Instituto Mexicano del Seguro Social
People needed: 108
Starts: 2024-08-14
Expected to finish: 2025-11-14
Last updated by the study team: 2024-09-19

Who can join

Age: 18 and older, up to 80. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

Virologically suppressed for at least 48 weeks prior to study entry
Coming from a regimen containing Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF), Dolutegravir/Lamivudine/Abacavir (DTG/3TC/ABC), or, Dolutegravir/Tenofovir Disoproxil Fumarate/Emtricitabine (DTG+TDF/FTC) with no known failures to integrase inhibitors for al least 48 weeks.
BMI ≥25 kg/m2 at screening and
Unintentional weight gain of \>10% from baseline (prior to INSTI initiation) within 1-3 years of starting INSTI ART, with no other apparent medical reason to explain the weight gain (concomitant medication use, Cushing's disease, recent prolonged hospitalization, etc.), in the opinion of the site investigator.
Body fat percentage \>20%
No indication or plans to add or change medications associated with significant weight change during the study period.
Participants currently receiving antipsychotics, antidepressants, anticonvulsants/mood stabilizers, and thyroid replacement hormones without dose modifications for at least 12 weeks prior to randomization
Participants currently receiving antidiabetics known to cause weight loss and without dose modifications for at least 24 weeks prior to randomization (GLP-1 receptor agonists, SGLT-2 inhibitors, insulin, metformin).
Agree to adhere to assigned ART during the study period
HIV-1 RNA screening \<50 copies/mL performed within 45 days prior to study entry.
GFR by CDK-EPI ≥60 mL/min
Alanine aminotransferase (ALT) and asparatate aminotransferase (AST) \< 90 IU/L
Thyroid profile (TSH, free T3 and free T4) prior to entering the study
Serum and urinary electrolytes, cystatin C, prior to entering the study

You may not qualify if…

Loss of social security
Allergy to any of the components of ART, previously unknown.
Withdrawal of informed consent
Acquiring HBV and/or HCV infection during follow-up.
HIV-1 RNA \>200 copies/mL in 2 consecutive determinations after having achieved virological suppression.
Early initiation or discontinuation of any of the following drugs after entering the study: antipsychotics (clozapine, olanzapine, risperidone); antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors) monoamine oxidase inhibitors, associated with weight gain; anticonvulsants/mood stabilizers (lithium, valproic acid) or associated with weight loss (topiramate); thyroid replacement hormones;
Change in dose or discontinuation of antidiabetic drugs that cause weight loss (GLP-1 receptor agonists, SGLT-2 inhibitors, insulin, metformin), after entering the study.
Planning to undergo or having undergone bariatric surgery.
Initiating significant dietary changes, advised by a nutritionist according to what was reported by the participant
Initiating or increasing physical exercise or enrolling in a structured weight loss regimen: \<250 minutes/week of moderate to intense activity

Where it is running

Hospital de infectología, Centro Médico Nacional La Raza — Mexico City, Azcapotzalco, Mexico (enrolling)
Hospital de infectología, Centro Médico Nacional La Raza — Mexico City, Azcapotzalco, Mexico (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.